Videra Surgical

Executive Summary

Videra Surgical is an oncology-focused medical device company dedicated to improving outcomes for breast cancer patients undergoing lumpectomy and subsequent radiation therapy. The company's technology addresses a critical challenge in breast-conserving surgery: accurately identifying the tumor bed to guide postoperative radiation, reducing the risk of local recurrence and minimizing damage to healthy tissue. Founded in 2016 and headquartered in San Francisco, Videra is developing a platform that integrates with surgical workflows to provide real-time, high-precision localization of the resection cavity. While the company is still in a relatively early stage with limited public information, its niche focus on a common oncology procedure positions it for potential adoption among radiation oncologists and surgeons. The value proposition aligns with the growing emphasis on personalized, targeted cancer care. However, success hinges on clinical validation, regulatory clearance, and market adoption in a competitive landscape.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance or De Novo classification for tumor bed visualization device40% success
• Q2 2027Publication of clinical trial results demonstrating improved target volume delineation35% success
• H1 2027Strategic partnership or distribution agreement with a radiation oncology equipment manufacturer30% success